Acrivon Therapeutics Inc [NASDAQ: ACRV] loss -17.59% or -0.35 points to close at $1.64 with a heavy trading volume of 16044954 shares.
The daily chart for ACRV points out that the company has recorded -79.63% loss over the past six months.
If we look at the average trading volume of 182.06K shares, ACRV reached to a volume of 16044954 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Acrivon Therapeutics Inc [ACRV]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ACRV shares is $12.29 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ACRV stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
KeyBanc Capital Markets have made an estimate for Acrivon Therapeutics Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on January 31, 2025. The new note on the price target was released on September 16, 2024, representing the official price target for Acrivon Therapeutics Inc stock.
The Average True Range (ATR) for Acrivon Therapeutics Inc is set at 0.36 The Price to Book ratio for the last quarter was 0.29, with the Price to Cash per share for the same quarter was set at 5.72.
Trading performance analysis for ACRV stock
Acrivon Therapeutics Inc [ACRV] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -9.39. With this latest performance, ACRV shares dropped by -37.16% in over the last four-week period, additionally sinking by -79.63% over the last 6 months – not to mention a drop of -83.30% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ACRV stock in for the last two-week period is set at 33.95, with the RSI for the last a single of trading hit 35.32, and the three-weeks RSI is set at 33.94 for Acrivon Therapeutics Inc [ACRV]. The present Moving Average for the last 50 days of trading for this stock 3.8300, while it was recorded at 1.9140 for the last single week of trading, and 6.4206 for the last 200 days.
Acrivon Therapeutics Inc [ACRV]: A deeper dive into fundamental analysis
Acrivon Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 10.55 and a Current Ratio set at 10.55.
Acrivon Therapeutics Inc [ACRV]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ACRV. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Acrivon Therapeutics Inc go to -1.43%.
An analysis of Institutional ownership at Acrivon Therapeutics Inc [ACRV]
There are presently around $74.43%, or 95.36%% of ACRV stock, in the hands of institutional investors. The top three institutional holders of ACRV stocks are: RA CAPITAL MANAGEMENT, L.P. with ownership of 8.34 million shares, which is approximately 23.083%. PERCEPTIVE ADVISORS LLC, holding 5.36 million shares of the stock with an approximate value of $$31.09 million in ACRV stocks shares; and PERCEPTIVE ADVISORS LLC, currently with $$12.31 million in ACRV stock with ownership which is approximately 5.8745%.
